The analysis of circulating tumor cell measurement of lung cancer by next genaration TelomeScan

• Project/Area Number: 15K09191
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Juntendo University
• Principal Investigator: TOGO Shinsaku 順天堂大学, 医学部, 准教授 (80365634)
• Co-Investigator(Kenkyū-buntansha): 小見山 博光 順天堂大学, 医学部, 非常勤講師 (30348982)
• Research Collaborator: NAMBA Yukiko 順天堂大学, 医学部, 助教 ; MINIWAN Torafu 順天堂大学, 医学部, 研究員
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 循環腫瘍細胞 / テロメスキャン / 上皮間葉転換 / 非小細胞肺がん / 癌幹細胞 / 肺癌 / 非小細胞肺癌 / テロメアーゼ

Outline of Final Research Achievements

Circulating tumor cells (CTCs) have a crucial role in the clinical outcome of cancer patients. The new telomerase-specific replication-selective adenovirus TelomeScan F35 (OBP-1101) can detect EMT-CTC without the detection based on epithelial markers. We measured the CTC from NSCLC patients showed mesenchymal phenotype CTC (EMT-CTC). Peripheral venous blood samples and clinicopathological data were collected from 123 NSCLC patients. The sensitivity of CTC detection was 69.1% and among the EMT-CTC samples, 46% were vimentin positive and 39.0% of non-EMT-CTC samples were EpCAM positive. Patients testing positive for EMT-CTCs at baseline had poor response to chemotherapy and decreased progression-free survival in comparison to those testing negative. TelomeScan F35 is a highly sensitive CTC detection system and will be a useful screening tool for early diagnosis of NSCLC patients. Mesenchymal-phenotype CTCs are crucial indicators of chemotherapeutic efficacy in NSCLC patients.

Research Products

• [Journal Article] Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients. (2017)
  • Author(s): Togo S, Katagiri N, Namba Y, Tulafu M, Nagahama K, Kadoya K, Takamochi K, Oh S, Suzuki K, Sakurai F, Mizuguchi H, Urata Y, Takahashi K.
  • Journal Title: Oncotarget Volume: 4 Issue: 21 Pages: 16818-16818
  • DOI: 10.18632/oncotarget.16818
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Efficient detection of human circulating tumor cells without significant production of false-positive cells by a novel conditionally replicating adenovirus. (2016)
  • Author(s): Sakurai F, Narii N, Tomita K, Togo S, Takahashi K, Machitani M, et al.
  • Journal Title: Mol Ther Methods Clin Dev. Volume: 3 Pages: 16001-16001
  • DOI: 10.1038/mtm.2016.1
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Presentation] Clinicopathological features and poor outcome for ALK inhibitors of squamous cell lung cancer with ALK-rearrangement (2017)
  • Author(s): Motomura Y1, Watanabe J1,2, Togo S1,2, Sumiyoshi I1, Namba Y4, Suina Y1, Mizuno T6, Kadoya K1, Iwai M1.2.8,Nagaoka T1,2, Sasaki S4, Hayashi T1,2, Uekusa T6, Abe K9, Urata Y9, Sakurai F10, Mizuguchi H10, Kato S5, Takahashi K1,2.
  • Organizer: IASLC WCLC 2017
  • Int'l Joint Research
• [Presentation] ALK阻害剤耐性獲得機序を確認したALK融合遺伝子変異陽性肺扁平上皮癌の1例 (2017)
  • Author(s): 水野 貴文、住吉 一誠、十合 晋作、田島 健、早川 乃介、推名健太郎、林 大久生、植草 利公、加藤 俊介、高橋 和久
  • Organizer: 日本呼吸器学会総会
• [Patent(Industrial Property Rights)] 細胞の検出方法 (2015)
  • Inventor(s): 十合/高橋/志田/大内/浦田
  • Industrial Property Rights Holder: 十合/高橋/志田/大内/浦田
  • Industrial Property Rights Type: 特許
  • Filing Date: 2015-04-01
  • Overseas